Detalles de la búsqueda
1.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
N Engl J Med
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38828946
2.
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Support Care Cancer
; 28(11): 5335-5342, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32128615
3.
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Support Care Cancer
; 25(2): 459-464, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27714530
4.
A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer.
J Med Assoc Thai
; 96 Suppl 2: S67-74, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23590024
5.
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Support Care Cancer
; 20(4): 849-55, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21505898
6.
C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
J Med Assoc Thai
; 95 Suppl 2: S199-207, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22574550
7.
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
J Clin Oncol
; 39(21): 2327-2338, 2021 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513313
Resultados
1 -
9
de 9
1
Próxima >
>>